finance News

BOSTON – BioAxone BioSciences, Inc., a biotechnology company committed to discovering and developing drugs for unmet needs of neurological conditions today announced the license of BA-1049, its innovative orally-available ROCK2 inhibitor that has promise as a therapeutic agent for the treatment of cerebral cavernous malformations (CCMs), to Neurelis, Inc. BioAxone...
NEW HAVEN, Conn. and LEUVEN, Belgium – Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced that they have entered into an exclusive global license and research agreement  to develop and commercialize first-in-class TRPM3 antagonists to address...
CAMBRIDGE, Mass. – bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company. bluebird bio will continue its work focused on severe genetic disease, with three near-term opportunities to bring transformative gene...
NEW YORK – Quest Diagnostics subsidiary Blueprint Genetics said on Thursday that it has partnered with the Helsinki Biobank and Helsinki University Hospital for a research initiative called Rare3k that aims to develop algorithms to accelerate the identification of patients who could benefit from genetic testing for certain rare diseases....
BOSTON – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. (“Astria” or the “Company”). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having patients serve as guiding stars....
DANBURY, Conn. & AUSTIN, Texas – CDISC and the National Organization for Rare Disorders (NORD®) have announced a partnership to develop global data standards for rare diseases. The data standards will be released in a Therapeutic Area User Guide that will be available at no cost on the CDISC website for researchers to...
ST. LOUIS, Dec. 15, 2020 — Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The transaction is subject to regulatory approvals and is expected to close by the end of 2020....
CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany and SOUTH SAN FRANCISCO, Cal. – Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (Nasdaq: TWST), a Company enabling customers to succeed through its offering of high-quality synthetic...